UroGen Pharma Ltd. — Director's Dealing 2019

Mar 7, 2019

SEC Form 3/A — Form 3/A

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-01-01

Reporting Person: Schoenberg Mark (Chief Medical Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	5287	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Restricted Stock Units	$		Ordinary Shares (8334)		Direct

Footnotes

F1: The original Form 3 did not reflect that a portion of the restricted stock units reported on Table II had vested, and therefore the number of ordinary shares reported on Table I was understated by 4,166 shares.

F2: On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of two years. The original Form 3 incorrectly stated the initial vesting date as December 7, 2019, and therefore did not reflect that 1/3rd of the RSUs had vested.

F3: Each RSU represents a contingent right to receive one ordinary share of the Issuer.